PharmaTher Holdings Ltd. (PHRRF)
PHRRF Stock Price Chart
Explore PharmaTher Holdings Ltd. interactive price chart. Choose custom timeframes to analyze PHRRF price movements and trends.
PHRRF Company Profile
Discover essential business fundamentals and corporate details for PharmaTher Holdings Ltd. (PHRRF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Jan 2021
Employees
—
Website
https://www.pharmather.comCEO
Fabio Chianelli
Description
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.
PHRRF Financial Timeline
Browse a chronological timeline of PharmaTher Holdings Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 24 Apr 2025
EPS came in at -$0.00 .
Earnings released on 30 Nov 2024
EPS came in at -$0.00 .
Earnings released on 31 Aug 2024
EPS came in at -$0.00 surpassing the estimated -$0.02 by +85.55%.
Earnings released on 31 May 2024
EPS came in at -$0.00 surpassing the estimated -$0.02 by +86.41%.
Earnings released on 29 Feb 2024
EPS came in at -$0.00 surpassing the estimated -$0.02 by +86.28%.
Earnings released on 30 Nov 2023
EPS came in at -$0.01 surpassing the estimated -$0.01 by +39.89%.
Earnings released on 31 Aug 2023
EPS came in at -$0.01 surpassing the estimated -$0.01 by +24.66%.
Earnings released on 31 May 2023
EPS came in at -$0.01 surpassing the estimated -$0.01 by +9.03%.
Earnings released on 28 Feb 2023
EPS came in at -$0.01 surpassing the estimated -$0.01 by +57.13%.
Earnings released on 26 Jan 2023
EPS came in at -$0.03 falling short of the estimated -$0.01 by -200.00%.
Earnings released on 24 Oct 2022
EPS came in at -$0.01 matching the estimated -$0.01.
Earnings released on 28 Sept 2022
EPS came in at $0.00 surpassing the estimated $0.00 by +111.54%.
Earnings released on 25 Apr 2022
EPS came in at -$0.01 surpassing the estimated -$0.06 by +83.33%.
Earnings released on 27 Jan 2022
EPS came in at -$0.00 falling short of the estimated -$0.00 by -80.82%.
Earnings released on 27 Oct 2021
EPS came in at -$0.01 matching the estimated -$0.01.
Earnings released on 7 Sept 2021
EPS came in at $0.01 surpassing the estimated $0.00 by +150.00%.
Earnings released on 29 Apr 2021
EPS came in at $0.05 .
Earnings released on 28 Jan 2021
EPS came in at -$0.01 .
Earnings released on 15 Oct 2020
EPS came in at -$0.01 .
PHRRF Stock Performance
Access detailed PHRRF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.